Viral based vaccine TG4010 induces broadening of specific immune response and improves outcome in advanced NSCLC

BACKGROUND: Advanced non-small cell lung cancer patients receiving TG4010, a therapeutic viral vaccine encoding human Mucin 1 and interleukin-2 in addition to standard chemotherapy, displayed longer overall survival in comparison to that of patients treated with standard chemotherapy alone. Our stud...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:J Immunother Cancer
Main Authors: Tosch, Caroline, Bastien, Bérangère, Barraud, Luc, Grellier, Benoit, Nourtier, Virginie, Gantzer, Murielle, Limacher, Jean Marc, Quemeneur, Eric, Bendjama, Kaïdre, Préville, Xavier
Format: Artigo
Jezik:Inglês
Izdano: BioMed Central 2017
Teme:
Research Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC5604422/
https://ncbi.nlm.nih.gov/pubmed/28923084
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40425-017-0274-x
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki